Celgene Quanticel Research, Inc.

Smithkline Beecham Corporation

Quanticel Pharmaceuticals, Inc.

Serenex, Inc.

Genentech, Inc.

Glaxosmithkline LLC

Glaxo Wellcome Inc.

Esanex, Inc.

Hengrui (usa) Ltd.

James Marvin Veal

Jeffrey Alan Stafford

Toufike Kanouni

Young K Chen

Michael Brennan Wallace

Zhe Nie

Stephen W Kaldor

Amogh Boloor

Philip Anthony Harris

Thomas E Barta

Mui Cheung

Karen Elizabeth Lackey

Scott Howard Dickerson

Lee Frederick Kuyper

Kenneth He Huang

Gunnar J Hanson

Juan Manuel Betancort

Michael John Bennett

Robert Neil Hunter, Iii

Lindsay A Hinkley

Lifeng Geng

Jeron Eaves

Michael Luzzio

Matthew Michael Kreilein

Stephen Thomas Davis

Paula Alessandra Tavares-Greco

Duncan Herrick Walker

Kevin Hinkle

Jeffery Alan Stafford

Christopher McBride

Robert Anthony Mook

Lynnie Lin Trzoss

Stephen V Frye

Michael Robert Peel

Emilie Despagnet Smith

Ryan Stansfield

Ronda Davis

Michael Brennen Wallace

Juan Manual Betancort

Francis Xavier Tavares

Steven T Staben

Richard Pastor

Matthew Volgraf

Craig Stivala

David Kendall Jung

Robert Walton McNutt, Jr

Robert N Atkinson

Tara Renae Rheault

Douglas McCord Sammond

Jennifer Gabriel Badiang

Hideyuki Sato

Kirk Stevens

Masaichi Hasegawa

Kristen Elizabeth Nailor

Naohiko Nishigaki

Wei Ma

Yoshiaki Washio

Satoru Ida

Kenneth H Huang

Ronda Gayle Davis-Ward

Christopher P Lauderman

Andy Ommen

Michael John Reno

Andy J Ommen

Kazuya Kano

Rob I West

Christopher Mcbride

Juan Manuel Bettancort

Amogh Bloor

The present invention relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted pyrido[3,4-d]pyrimidin-4-one derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition of histone demethylase. Furthermore, the subject compounds and compositions are useful for the treatment of cancer, such as prostate cancer, breast cancer, bladder cancer, lung cancer and/or melanoma and the like.

Histone demethylase inhibitors

The present invention relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted heterocyclic derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition of lysine specific demethylase-1. Furthermore, the subject compounds and compositions are useful for the treatment of cancer.

Inhibitors of lysine specific demethylase-1

The present embodiments provide for substituted triazolylpyridine derivative compounds, and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for modulating the activity of histone demethylase enzymes. Additionally, the subject compounds and compositions are useful for the treatment of cancer or other neoplastic diseases, or maladies associated with abnormal histone demethylase activity. Accordingly, the substituted triazolylpyridine derivative compounds described herein are useful in methods and medicaments for treating cancer.

The present disclosure relates to novel sulfonylurea and sulfonyl thiourea compounds and related compounds and their use in treating a disease or condition responsive to modulation of cytokines such as IL-1&#x3b2; and IL-18, modulation of NLRP3 or inhibition of the activation of NLRP3 or related components of the inflammatory process.

Chemical compounds as inhibitors of interleukin-1 activity

Described herein is the bromodomain inhibitor 4-[2-(cyclopropylmethoxy)-5-methylsulfonylphenyl]-2-methylisoquinolin-1-one, including crystalline forms, amorphous forms, solvates, and hydrates thereof, as well as pharmaceutical compositions that include this bromodomain inhibitor. In some embodiments, the pharmaceutical composition comprises 4-[2-(cyclopropylmethoxy)-5-methylsulfonylphenyl]-2-methylisoquinolin-1-one that has been processed by micronization or spray dried dispersion. In some embodiments, the pharmaceutical composition further comprises at least one polymer. In some embodiments, the pharmaceutical composition comprises a solid polymer matrix comprising 4-[2-(cyclopropylmethoxy)-5-methylsulfonylphenyl]-2-methylisoquinolin-1-one and at least one polymer. Pharmaceutical compositions comprising 4-[2-(cyclopropylmethoxy)-5-methylsulfonylphenyl]-2-methylisoquinolin-1-one are useful for the treatment of cancer or neoplastic disease.

Bromodomain inhibitor

The present invention relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted amidopyridine or amidopyridazine derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition histone demethylase. Furthermore, the subject compounds and compositions are useful for the treatment of cancer, such as prostate cancer, breast cancer, bladder cancer, lung cancer and/or melanoma and the like.

The present disclosure relates to novel sulfonylurea compounds and related compounds useful in treating a disorder responsive to modulation of cytokines such as IL-1&#x3b2; and IL-18, modulation of NLRP3 or inhibition of the activation of NLRP3 or related components of the inflammatory process.

Sulfonylurea compounds as inhibitors of interleukin-1 activity

The present invention relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted heterocyclic derivative compounds and pharmaceutical compositions comprising said compounds as exemplified as follows, The subject compounds and compositions are useful for inhibition of lysine specific demethylase-1. Furthermore, the subject compounds and compositions are useful for the treatment of cancer, such as prostate cancer, breast cancer, bladder cancer, lung cancer and/or melanoma and the like.

The present invention relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted heterocyclic derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition of lysine specific demethylase-1. Furthermore, the subject compounds and compositions are useful for the treatment of cancer, such as prostate cancer, breast cancer, bladder cancer, lung cancer and/or melanoma and the like.

Growing community of inventors

Apex, NC, United States of America

James Marvin Veal